A successful risk management programme needs to be all-encompassing and not focused solely on prescriptive regulatory requirements.
The life sciences industry continues to become ever more dynamic and complex. Comprising bio-technology, pharmaceutical and medical devices as well as other industry sub sectors, this industry remains highly regulated, highly capital intensive and highly reliant on data quality.
Consolidation in the industry continues with strategic acquisitions and alliances happening most notably to strengthen and improve product pipeline, R&D capabilities and in certain cases secure innovative technologies.
Published from Grant Thornton Ireland